Boissel JP - Search Results

1

Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups.

Gasowski J, Fagard RH, Staessen JA, Grodzicki T, Pocock S, Boutitie F, Gueyffier F, Boissel JP; INDANA Project Collaborators. Gasowski J, et al. Among authors: boissel jp. J Hypertens. 2002 Jan;20(1):145-51. doi: 10.1097/00004872-200201000-00021. J Hypertens. 2002. PMID: 11791038 Free article. Clinical Trial.

2

Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments.

Boissel JP, Gueyffier F, Boutitie F, Pocock S, Fagard R. Boissel JP, et al. Fundam Clin Pharmacol. 2005 Oct;19(5):579-84. doi: 10.1111/j.1472-8206.2005.00356.x. Fundam Clin Pharmacol. 2005. PMID: 16176337

3

J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data.

Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP; INDANA Project Steering Committee. INdividual Data ANalysis of Antihypertensive intervention. Boutitie F, et al. Among authors: boissel jp. Ann Intern Med. 2002 Mar 19;136(6):438-48. doi: 10.7326/0003-4819-136-6-200203190-00007. Ann Intern Med. 2002. PMID: 11900496

4

Treatment of high blood pressure and gain in event-free life expectancy.

Kassaï B, Boissel JP, Cucherat M, Boutitie F, Gueyffier F. Kassaï B, et al. Among authors: boissel jp. Vasc Health Risk Manag. 2005;1(2):163-9. doi: 10.2147/vhrm.1.2.163.64086. Vasc Health Risk Manag. 2005. PMID: 17315403 Free PMC article.

5

Risk reduction for stroke and coronary events.

Boissel JP, Gueyffier F, Boutitie F. Boissel JP, et al. Lancet. 2002 Apr 6;359(9313):1249; author reply 1250-1. doi: 10.1016/S0140-6736(02)08233-8. Lancet. 2002. PMID: 11955569 No abstract available.

6

Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit?

Kassai B, Gueyffier F, Boissel JP, Boutitie F, Cucherat M. Kassai B, et al. Among authors: boissel jp. J Clin Epidemiol. 2003 Oct;56(10):977-82. doi: 10.1016/s0895-4356(03)00159-8. J Clin Epidemiol. 2003. PMID: 14568629

7

High Risk versus Proportional Benefit: Modelling Equitable Strategies in Cardiovascular Prevention.

Marchant I, Boissel JP, Nony P, Gueyffier F. Marchant I, et al. Among authors: boissel jp. PLoS One. 2015 Nov 3;10(11):e0140793. doi: 10.1371/journal.pone.0140793. eCollection 2015. PLoS One. 2015. PMID: 26529507 Free PMC article.

8

SCORE should be preferred to Framingham to predict cardiovascular death in French population.

Marchant I, Boissel JP, Kassaï B, Bejan T, Massol J, Vidal C, Amsallem E, Naudin F, Galan P, Czernichow S, Nony P, Gueyffier F. Marchant I, et al. Among authors: boissel jp. Eur J Cardiovasc Prev Rehabil. 2009 Oct;16(5):609-15. doi: 10.1097/HJR.0b013e32832da006. Eur J Cardiovasc Prev Rehabil. 2009. PMID: 20054289

9

Pharmacogenetics and responders to a therapy: theoretical background and practical problems.

Boissel JP, Gueyffier F, Cucherat M, Bricca G. Boissel JP, et al. Clin Chem Lab Med. 2003 Apr;41(4):564-72. doi: 10.1515/CCLM.2003.086. Clin Chem Lab Med. 2003. PMID: 12747604 Review.

10

The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests.

Kassaï B, Shah NR, Leizorovicza A, Cucherat M, Gueyffier F, Boissel JP. Kassaï B, et al. Among authors: boissel jp. J Clin Epidemiol. 2005 Oct;58(10):1042-51. doi: 10.1016/j.jclinepi.2005.02.024. J Clin Epidemiol. 2005. PMID: 16168350 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

437 results

Search Page